Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC
T he c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety ...
Hosted on MSN11mon
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
AbbVie Inc (NYSE: ABBV) announced topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression ...
pharmaphorum7d
FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag
Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The c-Met protein ...
The Victoria Advocate1mon
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...